Incyte (INCY) News Today $73.47 +1.54 (+2.14%) Closing price 04:00 PM EasternExtended Trading$73.46 0.00 (-0.01%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Incyte to Report Fourth Quarter and Year-End 2024 Financial ResultsJanuary 21 at 8:50 AM | finance.yahoo.comShort Interest in Incyte Co. (NASDAQ:INCY) Decreases By 13.1%Incyte Co. (NASDAQ:INCY - Get Free Report) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 5,100,000 shares, a decline of 13.1% from the December 15th total of 5,870,000 shares. Approximately 2.7% of the shares of the stock are sold short. Based on an average trading volume of 1,960,000 shares, the short-interest ratio is presently 2.6 days.January 19 at 1:22 PM | marketbeat.comIncyte Co. (NASDAQ:INCY) Stock Holdings Trimmed by Shikiar Asset Management Inc.Shikiar Asset Management Inc. cut its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 3.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 161,690 shares of the biopharmaceutical company's stock after sellinJanuary 18 at 8:27 AM | marketbeat.comHennion & Walsh Asset Management Inc. Acquires 11,120 Shares of Incyte Co. (NASDAQ:INCY)Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 45.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,708 shares of the biopharmaceutJanuary 18 at 4:07 AM | marketbeat.comWhat You Need to Know Ahead of Incyte's Earnings ReleaseJanuary 17, 2025 | msn.comIncyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial SizesJanuary 16, 2025 | marketwatch.comIncyte, Syndax announce FDA approval for Niktimvo vial sizesJanuary 16, 2025 | markets.businessinsider.comIncyte Co. (NASDAQ:INCY) Shares Acquired by Contravisory Investment Management Inc.Contravisory Investment Management Inc. raised its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 50.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,854 shares of the biJanuary 16, 2025 | marketbeat.comAnalysts Set Incyte Co. (NASDAQ:INCY) Price Target at $76.29January 16, 2025 | americanbankingnews.comCHURCHILL MANAGEMENT Corp Acquires 4,869 Shares of Incyte Co. (NASDAQ:INCY)CHURCHILL MANAGEMENT Corp boosted its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 2.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 178,922 shares of the biopharmaceutical company's stock after purchasingJanuary 16, 2025 | marketbeat.comClaro Advisors LLC Takes Position in Incyte Co. (NASDAQ:INCY)Claro Advisors LLC purchased a new stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,698 shares of the biopharmaceutical company's stock, valJanuary 16, 2025 | marketbeat.comIncyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial SizesJanuary 15, 2025 | prnewswire.comJP Morgan 2025: Incyte expects period of ‘defining catalysts’January 15, 2025 | finance.yahoo.comIncyte’s Strategic Challenges: Navigating Post-Jakafi Growth Gap and Limited Business Development CapacityJanuary 14, 2025 | markets.businessinsider.comJMP Securities Reaffirms "Market Perform" Rating for Incyte (NASDAQ:INCY)JMP Securities reiterated a "market perform" rating on shares of Incyte in a report on Tuesday.January 14, 2025 | marketbeat.comIncyte Stock: Hold Rating Amid Patent Cliff Concerns and Awaited Clinical MilestonesJanuary 14, 2025 | markets.businessinsider.comPallas Capital Advisors LLC Makes New Investment in Incyte Co. (NASDAQ:INCY)Pallas Capital Advisors LLC purchased a new stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 14,571 shares of the biopharmaceutical company's stJanuary 14, 2025 | marketbeat.comIncyte Corp (INCY) Unveils Promising Developments and Future Catalysts at J.P. ...January 13, 2025 | gurufocus.comIncyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 13, 2025 | businesswire.comIncyte Co. (NASDAQ:INCY) Given Consensus Rating of "Hold" by AnalystsIncyte Co. (NASDAQ:INCY - Get Free Report) has earned a consensus recommendation of "Hold" from the twenty brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and eight haveJanuary 13, 2025 | marketbeat.comCantor Fitzgerald Reaffirms "Neutral" Rating for Incyte (NASDAQ:INCY)January 12, 2025 | americanbankingnews.comIncyte: Multiple Drug Launches Bode Well For Future GrowthJanuary 11, 2025 | seekingalpha.comIncyte: Multiple Drug Launches Bode Well For Future GrowthJanuary 11, 2025 | seekingalpha.comIncyte's (INCY) Neutral Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reaffirmed a "neutral" rating on shares of Incyte in a research report on Friday.January 10, 2025 | marketbeat.comIncyte Corporation (INCY) Announces Executive Leadership ChangeJanuary 10, 2025 | gurufocus.comIncyte Announces Retirement of Executive VP Barry FlannellyJanuary 10, 2025 | tipranks.comJPMorgan Chase & Co. Sells 209,133 Shares of Incyte Co. (NASDAQ:INCY)JPMorgan Chase & Co. trimmed its position in Incyte Co. (NASDAQ:INCY - Free Report) by 42.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 285,090 shares of the biopharmaceutical cJanuary 10, 2025 | marketbeat.comIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2025 | businesswire.comIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2025 | businesswire.comIncyte (INCY) Receives a Hold from Truist FinancialJanuary 8, 2025 | markets.businessinsider.comIncyte price target raised to $75 from $74 at RBC CapitalJanuary 7, 2025 | markets.businessinsider.comIncyte’s Strategic Balancing Act: Promising Drug Prospects Amid Competitive and Intellectual Property ChallengesJanuary 7, 2025 | markets.businessinsider.comCWA Asset Management Group LLC Purchases New Shares in Incyte Co. (NASDAQ:INCY)CWA Asset Management Group LLC acquired a new stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 27,984 shares of the biopharmaceutical company's stock, valued at approximately $1,933,000.January 7, 2025 | marketbeat.comCentre Asset Management LLC Has $9.40 Million Stock Holdings in Incyte Co. (NASDAQ:INCY)Centre Asset Management LLC decreased its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 8.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 136,154 shares of the biopharmaceutical company's stock after selJanuary 3, 2025 | marketbeat.comPrincipal Financial Group Inc. Sells 27,138 Shares of Incyte Co. (NASDAQ:INCY)Principal Financial Group Inc. decreased its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 10.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 220,750 shares of the biopharmaceutical company's stock aDecember 29, 2024 | marketbeat.comIs Incyte Stock Outperforming the Dow?December 24, 2024 | msn.comFranklin Resources Inc. Has $13.20 Million Holdings in Incyte Co. (NASDAQ:INCY)Franklin Resources Inc. trimmed its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 19.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 201,718 shares of the biopharmaceutical company's sDecember 21, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Stock Position Lowered by Sanctuary Advisors LLCSanctuary Advisors LLC reduced its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 53.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,056 shares of the biopharmaceutical companyDecember 21, 2024 | marketbeat.comThe Analyst Verdict: Incyte In The Eyes Of 15 ExpertsDecember 20, 2024 | benzinga.comIncyte price target raised to $70 from $68 at Wells FargoDecember 20, 2024 | finance.yahoo.comIncyte (NASDAQ:INCY) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysWells Fargo & Company boosted their price objective on shares of Incyte from $68.00 to $70.00 and gave the stock an "equal weight" rating in a research report on Thursday.December 19, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Receives Consensus Recommendation of "Hold" from AnalystsShares of Incyte Co. (NASDAQ:INCY - Get Free Report) have been given an average rating of "Hold" by the twenty ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a hold recommendatiDecember 19, 2024 | marketbeat.comThomas Tray Sells 650 Shares of Incyte Co. (NASDAQ:INCY) StockDecember 18, 2024 | insidertrades.comInsider Selling: Incyte Co. (NASDAQ:INCY) Insider Sells 650 Shares of StockIncyte Co. (NASDAQ:INCY - Get Free Report) insider Thomas Tray sold 650 shares of the business's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $69.31, for a total value of $45,051.50. Following the transaction, the insider now directly owns 23,312 shares of the company's stock, valued at approximately $1,615,754.72. The trade was a 2.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.December 17, 2024 | marketbeat.comIncyte’s Mixed Clinical Results and Financial Challenges Lead to Hold RatingDecember 17, 2024 | markets.businessinsider.comUBS Group Initiates Coverage on Incyte (NASDAQ:INCY)UBS Group began coverage on Incyte in a report on Tuesday. They issued a "neutral" rating and a $77.00 price target on the stock.December 17, 2024 | marketbeat.comOrion Portfolio Solutions LLC Takes Position in Incyte Co. (NASDAQ:INCY)Orion Portfolio Solutions LLC bought a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 11,655 shares of the biopharmaceutical company's stock, valued at approximately $770,0December 17, 2024 | marketbeat.comWellington Management Group LLP Trims Stock Position in Incyte Co. (NASDAQ:INCY)Wellington Management Group LLP reduced its position in Incyte Co. (NASDAQ:INCY - Free Report) by 59.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 71,730 shares of the biopharmaceutical company's stock after selling 103,09December 17, 2024 | marketbeat.comToronto Dominion Bank Purchases 7,812 Shares of Incyte Co. (NASDAQ:INCY)Toronto Dominion Bank raised its holdings in Incyte Co. (NASDAQ:INCY - Free Report) by 16.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,084 shares of the biopharmaceutical company's stock afterDecember 16, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Sold by Public Employees Retirement System of OhioPublic Employees Retirement System of Ohio lessened its position in Incyte Co. (NASDAQ:INCY - Free Report) by 17.9% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 58,971 shares of the biopharmaceutical company's stock after selling 12,843 shares during the periDecember 16, 2024 | marketbeat.com Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address INCY Media Mentions By Week INCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INCY News Sentiment▼0.790.60▲Average Medical News Sentiment INCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INCY Articles This Week▼1411▲INCY Articles Average Week Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today Neurocrine Biosciences News Today BioMarin Pharmaceutical News Today Exelixis News Today Exact Sciences News Today Repligen News Today Halozyme Therapeutics News Today Madrigal Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INCY) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
